Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery.
Present investigation was aimed at developing an oral insulin delivery system based on hydroxypropyl beta cyclodextrin-insulin (HPbetaCD-I) complex encapsulated polymethacrylic acid-chitosan-polyether (polyethylene glycol-polypropylene glycol copolymer) (PMCP) nanoparticles. Nanoparticles were prepared by the free radical polymerization of methacrylic acid in presence of chitosan and polyether in a solvent/surfactant free medium. Dynamic light scattering (DLS) experiment was conducted with particles dispersed in phosphate buffer (pH 7.4) and size distribution curve was observed in the range of 500-800 nm. HPbetaCD was used to prepare non-covalent inclusion complex with insulin and complex was analyzed by Fourier transform infrared (FTIR) and fluorescence spectroscopic studies. HPbetaCD complexed insulin was encapsulated into PMCP nanoparticles by diffusion filling method and their in vitro release profile was evaluated at acidic/alkaline pH. PMCP nanoparticles displayed good insulin encapsulation efficiency and release profile was largely dependent on the pH of the medium. Enzyme linked immunosorbent assay (ELISA) study demonstrated that insulin encapsulated inside the particles was biologically active. Trypsin inhibitory effect of PMCP nanoparticles was evaluated using N-alpha-benzoyl-L-arginine ethyl ester (BAEE) and casein as substrates. Mucoadhesive studies of PMCP nanoparticles were conducted using freshly excised rat intestinal mucosa and the particles were found fairly adhesive. From the preliminary studies, cyclodextrin complexed insulin encapsulated mucoadhesive nanoparticles appear to be a good candidate for oral insulin delivery.
Sajeesh
S
S
Division of Biosurface Technology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram 695012, Kerala, India.
Sharma
Chandra P
CP
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000268:Adhesiveness; D000284:Administration, Oral; D000818:Animals; D002364:Caseins / Q000378:metabolism; D048271:Chitosan / Q000737:chemistry; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005453:Fluorescence; D007328:Insulin / Q000008:administration & dosage* / Q000737:chemistry; D007413:Intestinal Mucosa / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008027:Light; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods; D010316:Particle Size; D011109:Polymethacrylic Acids / Q000737:chemistry; D051381:Rats; D012542:Scattering, Radiation; D017550:Spectroscopy, Fourier Transform Infrared / Q000379:methods; D014361:Trypsin Inhibitors / Q000008:administration & dosage / Q000737:chemistry; D047392:beta-Cyclodextrins / Q000032:analysis / Q000737:chemistry*
D002364:Caseins; D007328:Insulin; D011109:Polymethacrylic Acids; D014361:Trypsin Inhibitors; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; C030613:polymethacrylic acid; D048271:Chitosan